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CASE REPORT
Sarcoid-like reaction in a patient recovering
from coronavirus disease 19 pneumonia
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Shinya U. Amano, MD, PhD,d Nikki A. Levin, MD, PhD,b Mary Callery O’Brien, MD,e and Karen Wiss, MDb,f
Newark, New Jersey; Worcester, Massachusetts; East Greenwich, Rhode Island
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INTRODUCTION
As coronavirus disease 2019 (COVID-19) cases
continue to increase, so do the reported extrapulmo-
nary manifestations of this disease. To date,
described dermatologic manifestations of COVID-
19 include pernio-like acral nodules, dengue
feverelike petechiae, vesiculobullous eruptions,
pityriasis rosea and viral-like exanthems, retiform
purpura, and livedo reticularis.1 We describe a
patient with new-onset, biopsy confirmed sarcoid-
like reaction in the setting of COVID-19 pneumonia
and postulate a role for this immunologic reaction in
hastening disease recovery.
CASE REPORT
A 72-year-old white womanwith amedical history
of asthma, hypertension, hyperlipidemia, obstruc-
tive sleep apnea, and seizure disorder was seen in
the dermatology department describing a 2-day
history of painful, violaceous nodules on the anterior
shins, lateral thighs, submental neck, and glabella.
Two weeks prior, she was admitted for treatment of
polymerase chain reaction epositive COVID-19eas-
sociated pneumonia with no associated skin find-
ings. Upon discharge, her pulmonary symptoms and
fatigue resolved, and she subsequently tested nega-
tive for severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2). Clinical examination was
notable for tender, indurated nodules on the right
shin and bilateral lateral thighs and nontender
nodules noted on the glabella and submental chin.
The anterior shin lesions were suspicious for
erythema nodosum (Fig 1). As facial involvement is
atypical for this process, biopsies were taken of
both the leg and chin. Pathologic findings from both
specimens included well-formed noncaseating
granulomas in the subcutaneous tissue, suspicious
for granulomatous panniculitis and suggestive of
sarcoidosis. Erythema nodosum was not favored as
the panniculitis was predominantly lobular (Fig 2).
Acid-fast, periodic acideSchiff, and Gram stains
were negative, and no evidence of vasculitis was
observed.
At one-week follow-up, the patient reported sig-
nificant simultaneous improvement in sizeand tender-
ness of the nodules after twice daily application
of clobetasol ointment. The lesions continued to
improve but were still present at the last follow-up
visit after 25 days from initial onset. A comprehensive
workupwasunremarkable, including completeblood
count, serum angiotensin-converting enzyme (ACE)
levels, complete metabolic panel, serum and urine
calcium, chest radiograph, and electrocardiogram.
DISCUSSION
Noncaseating granulomas, often called sarcoidal
granulomas or a sarcoid-like immune reaction, are
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histologically indistinguishable.2 Although the etiol-
ogy of sarcoidosis is largely unknown, cross-reaction
to an infectious antigen has been proposed as an
initiating factor.3 Sarcoid-like immune reactions are
an immunologic response to immunogenic antigens
from certain infectious or noninfectious processes
and have been documented in patients with occupa-
tional exposures to beryllium, zirconium, and
aluminum; on immunotherapy for cancer treatment;
and in reaction to viral and bacterial infections.2,4 To
our knowledge, no COVID-induced sarcoid-like re-
actions have been reported.
Because of the close temporal relationship be-
tween her eruption and the infection, we propose
that the noncaseating granulomas in this case are a
sarcoid-like immune reaction to SARS-CoV-2.2 ACE
levels are often elevated in sarcoidosis and sarcoid-
like reactions, as ACE is produced by epithelioid cells
within granulomas.5 The ACE2 receptor has been
implicated as the entry point for SARS-CoV-2, and
expression of this receptor is inversely related to ACE
levels; increased ACE levels suppress ACE2 expres-
sion and vice versa.6 It has been theorized that
COVID-19 infection leads to downregulation of the
ACE2 receptor, thus increasing ACE2 levels.6 We
postulate that, in the case of pulmonary involvement,
the ACE-producing noncaseating granulomas in a
sarcoid-like immune reaction could act to decrease
additional viral induction into cells by further down-
regulating ACE2 receptor expression. Therefore,
sarcoid-like reactions in COVID-19 patients could
be a sign of convalescence rather than a sign of acute
infection itself, as evidenced by the onset of our
patient’s cutaneous findings as her disease waned.
Although primary sarcoidosis can occur at any age, it
is more common in young and middle-aged adults
and would be unusual in a patient in her 70s without
a history.7 The rapidly resolving nature of the lesions
and negative systemic workup further support
COVID-induced sarcoid-like reaction rather than a
diagnosis of primary sarcoidosis.
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Fig 1. Indurated violaceous nodules on the glabella, submental chin, and anterior shin.
Fig 2. Subcutaneous fat notable for well-formed non-
caseating sarcoidal granulomas in a predominantly lobular
distribution with some spillover into the septae and deep
dermis. (Hematoxylin-eosin stain; original magnification:
320.)
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